Head-To-Head Review: Windtree Therapeutics (WINT) & The Competition
Windtree Therapeutics (NASDAQ: WINT) is one of 93 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Windtree Therapeutics to similar businesses based on the strength of its risk, valuation, profitability, dividends, analyst recommendations, earnings and institutional ownership.
Risk and Volatility
Windtree Therapeutics has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Windtree Therapeutics’ peers have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.
Earnings & Valuation
This table compares Windtree Therapeutics and its peers revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Windtree Therapeutics||$3.23 million||-$28.34 million||-0.04|
|Windtree Therapeutics Competitors||$223.74 million||$57.84 million||-0.98|
Windtree Therapeutics’ peers have higher revenue and earnings than Windtree Therapeutics. Windtree Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
36.8% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 1.3% of Windtree Therapeutics shares are owned by company insiders. Comparatively, 19.6% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Windtree Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Windtree Therapeutics Competitors||-919.42%||-189.81%||-26.55%|
This is a breakdown of recent ratings and recommmendations for Windtree Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Windtree Therapeutics Competitors||164||548||1210||16||2.56|
Windtree Therapeutics presently has a consensus price target of $8.00, indicating a potential upside of 4,034.37%. As a group, “Biotechnology” companies have a potential upside of 55.15%. Given Windtree Therapeutics’ higher probable upside, research analysts plainly believe Windtree Therapeutics is more favorable than its peers.
Windtree Therapeutics peers beat Windtree Therapeutics on 7 of the 12 factors compared.
Windtree Therapeutics Company Profile
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.
Receive News & Ratings for Windtree Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.